Since the beginning of this year, all localities have actively explored and promoted the inclusion of assisted reproduction in medical insurance, and relevant support policies have been gradually improved. Driven by the huge market demand prospect, many listed companies are also stepping up their layout.
Assisted childbirth is included in the medical insurance policy.
According to the policy of Hangzhou, "West Lake Yilianbao" will give a certain amount of subsidy to the embryo culture and embryo transfer expenses during the treatment in the provincial and municipal 3A medical institutions with specific assisted reproductive qualifications in Hangzhou, in which the reimbursement limit of embryo culture expenses is 0.10.5 million yuan/year, and the reimbursement limit of embryo transfer expenses is 0.10.5 million yuan/year, which can be based on actual projects within the annual limit.
The news said that at the end of this year 10, the National Health Planning Commission held a forum on population work. The meeting proposed that it is necessary to speed up the establishment of a fertility support policy system and coordinate the introduction of more supporting measures; It is necessary to improve the working mechanism such as target management responsibility system, strengthen overall planning, policy coordination and work implementation, and promote long-term balanced population development.
Earlier, the Zhejiang Provincial Health and Wellness Committee publicly stated that it actively promoted the inclusion of assisted reproductive technology projects in medical insurance.
Some institutions said that the current cost of assisted reproduction is relatively high. After the assisted reproductive project is included in medical insurance, more people will have the opportunity to have assisted reproductive treatment, which will help promote the healthy development of assisted reproductive industry in the long run.
The policy support system is improving day by day.
According to industry insiders, in recent years, the state has successively introduced the "two-child policy" and "three-child policy" to further meet the people's reproductive health needs.
In August this year, the National Health Commission, the National Development and Reform Commission and other departments 17 issued the Guiding Opinions on Further Perfecting and Implementing Positive Fertility Support Measures, which clearly stated for the first time that it would guide local governments to comprehensively consider the financial affordability of medical insurance (including maternity insurance) and related technical specifications, and gradually bring appropriate labor analgesia and assisted reproductive technology projects into the scope of fund payment according to procedures.
Prior to this, many medical insurance management departments indicated that they would gradually explore the inclusion of assisted reproductive technology projects in medical insurance. Among them, the Hunan Provincial Medical Insurance Bureau said in May this year that it would gradually explore the inclusion of therapeutic assisted reproductive technology in medical insurance and include it in the scope of medical insurance payment according to procedures. Suzhou Medical Insurance Bureau also stated that assisted reproductive technology with large clinical demand will be included in the scope of medical insurance payment in due course.
In addition, as early as February this year, Beijing Medical Insurance Bureau also issued a notice to include 16 assisted reproductive technology items such as intrauterine insemination and embryo transfer, which are common in outpatient clinics, into medical insurance.
Broad market prospect
According to an insider, although the subject of assisted reproductive technology in China started late, it has developed very rapidly in recent years. However, at present, the penetration rate of assisted reproductive services in China is still low, and there is a broad market development space in the future.
According to reports, the current assisted reproductive industry chain can be roughly divided into upstream assisted reproductive drugs, testing reagents and equipment suppliers, midstream "Internet plus assisted reproductive services" online platform, and downstream assisted reproductive medical service providers. Attracted by the huge market prospect, in recent years, listed companies such as Jin Xin Reproductive, International Medicine, Everyone Weikang and Hanshang Group are stepping up their layout.
The research report recently released by Industrial Securities pointed out that the prosperity of assisted reproductive industry continued to rise under the impetus of population policy. In addition, the increasingly strict supervision of the assisted reproductive industry will also promote the standardized development of the whole industry.
Recently, the assisted reproductive sector has once again stepped out of a wave of rising prices. As of June 25th, 165438+, the assisted reproductive index was 44 10.53.